doi: 10.1074/jbc.C400258200
For muscle regeneration and systemic recovery , TB500 provides broader benefits
The following adverse effects were reported in patients receiving semaglutide injection or oral tablets across all clinical trials and at incidences higher than with placebo: nausea (11% to 44%), vomiting (5% to 24%), diarrhea (8.5% to 30%), abdominal pain (5.7% to 20%), abdominal distention (2% to 7%), constipation (3.1% to 24%), dyspepsia (0.6% to 9%), decreased appetite (6% to 9%), eructation (0.6% to 7%), flatulence (0.4% to 6%), gastroesophageal reflux disease (1.5% to 5%), gastroenteritis (4% to 6%), and gastritis (0.4% to 4%)
the only ASV identified for Staphylococcus mapped to Staphylococcus xylosus , and the only ASV found for UBA1819 mapped to Ruthenibacterium lactatiformans
Questions are expected and answered